Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 390677 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
ElectronicAdd to Basket



Does the Treatment of Huntingtons Disease Represent a Commercial Opportunity?
Decision Resources, Inc., Aug 2007, Pages: 22


  Description  
  Table of Contents  
  Companies Mentioned  
    
    
   
 Enquire before Buying  
 Send to a Friend  

Huntington’s disease (HD) is a genetic neurological disorder characterized by uncontrolled body movements and cognitive dysfunction. No drugs are approved to treat the disorder, leaving a high level of unmet need.

Commercial opportunity abounds, but the small patient population deters some companies. However, because of novel treatment approaches, interest in HD research is growing and companies may be able to tap into the enormous commercial potential, especially if a drug can treat multiple neurological diseases.

Questions Answered in This Spectrum Report:
-Huntington’s disease has a small patient population across all markets. What are the advantages and disadvantages for drug developers? What effect does orphan-drug status have on a drug’s potential?
-No therapies are approved specifically for HD; all current therapies are used off-label and provide only symptomatic relief. Which drugs are being investigated in clinical trials? What are the difficulties? When will a drug launch for HD?
-Novel treatment approaches including disease-modifying stem-cell and gene therapies are making some headway. What companies are investigating HD treatments and what are the most promising treatment approaches? At what stage are these treatments, and what are the chances of their launching for HD?

Scope:
-Overview of Huntington’s disease: genetics, pathophysiology, epidemiology, symptoms, and diagnosis.
-Current treatment approach: no therapies are approved for HD; several drugs are used off-label to treat symptoms.
-Emerging therapies: disease-modifying agents, including Amarin’s Miraxion (Phase III) and Avicena’s HD-02 (Phase II), and symptomatic therapies, including Prestwick’s Xenazine (preregistered) and NeuroSearch’s ACR-16 (Phase II).
-Novel treatment approaches: stem-cell transplantation and gene therapy.
-Challenges and outlook: the future of the HD market.



Customers who bought this item also bought

Chinese Markets for Cancer Treatment Drugs

Treatment Algorithms: Cancer Pain - Physician Awareness and Novel Drug Delivery Will Drive Market Opportunities

Cancer Drug Discoveries: What the Future Holds

Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities

Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success

Impact of Nanotechnology in Water and Wastewater Treatment

New Approaches to the Treatment of Non-Hodgkins Lymphoma

Triple Progress Analysis - Melanoma, Colorectal & Lung Cancer



Top of page


   All rights reserved. � Copyright 2008 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds